Could a cell therapy free liver transplant patients from lifelong drugs?
NCT ID NCT03577431
First seen May 10, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This early-phase study tests a new cell therapy in 9 liver transplant recipients. The goal is to see if giving patients their own specially trained immune cells (called Tregs) can allow them to safely stop or reduce their lifelong anti-rejection medications. The study focuses on safety and whether patients can remain drug-free for a year without rejecting their new liver.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital: Transplantation
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.